BRPI0709803B8 - compostos moduladores de benzimidazol de vr1, sais, processo de preparação do mesmo, seu uso e composição farmacêutica que os compreende - Google Patents

compostos moduladores de benzimidazol de vr1, sais, processo de preparação do mesmo, seu uso e composição farmacêutica que os compreende

Info

Publication number
BRPI0709803B8
BRPI0709803B8 BRPI0709803A BRPI0709803A BRPI0709803B8 BR PI0709803 B8 BRPI0709803 B8 BR PI0709803B8 BR PI0709803 A BRPI0709803 A BR PI0709803A BR PI0709803 A BRPI0709803 A BR PI0709803A BR PI0709803 B8 BRPI0709803 B8 BR PI0709803B8
Authority
BR
Brazil
Prior art keywords
benzimidazole
salts
preparation
pharmaceutical composition
modulating compounds
Prior art date
Application number
BRPI0709803A
Other languages
English (en)
Inventor
A Beauchamp Derek
Liu Jian
M Wells Kenneth
A Youngman Mark
R Player Mark
Brandt Michael
C Jetter Michele
L Calvo Raul
L Dax Scott
Patel Sharmila
H Parsons William
Pan Wenxi
S Cheung Wing
Lee Yu-Kai
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0709803A2 publication Critical patent/BRPI0709803A2/pt
Publication of BRPI0709803B1 publication Critical patent/BRPI0709803B1/pt
Publication of BRPI0709803B8 publication Critical patent/BRPI0709803B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

moduladores de benzimidazol de vr1. a invenção é direcionada a compostos de fórmula (i): (i) às composições farmacêuticas contendo tais compostos e a métodos de tratamento utilizando-os.
BRPI0709803A 2006-05-03 2007-04-17 compostos moduladores de benzimidazol de vr1, sais, processo de preparação do mesmo, seu uso e composição farmacêutica que os compreende BRPI0709803B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79750406P 2006-05-03 2006-05-03
US60/797,504 2006-05-03
PCT/US2007/066748 WO2007130780A2 (en) 2006-05-03 2007-04-17 Benzimidazole modulators of vr1

Publications (3)

Publication Number Publication Date
BRPI0709803A2 BRPI0709803A2 (pt) 2011-07-26
BRPI0709803B1 BRPI0709803B1 (pt) 2019-12-10
BRPI0709803B8 true BRPI0709803B8 (pt) 2021-05-25

Family

ID=38566108

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0709803A BRPI0709803B8 (pt) 2006-05-03 2007-04-17 compostos moduladores de benzimidazol de vr1, sais, processo de preparação do mesmo, seu uso e composição farmacêutica que os compreende

Country Status (37)

Country Link
US (3) US7951829B2 (pt)
EP (1) EP2021330B1 (pt)
JP (1) JP5302884B2 (pt)
KR (1) KR101434883B1 (pt)
CN (1) CN101511797B (pt)
AR (1) AR060840A1 (pt)
AT (1) ATE482201T1 (pt)
AU (1) AU2007248341C1 (pt)
BR (1) BRPI0709803B8 (pt)
CA (1) CA2651128C (pt)
CO (1) CO6160329A2 (pt)
CR (1) CR10479A (pt)
CY (1) CY1111269T1 (pt)
DE (1) DE602007009378D1 (pt)
DK (1) DK2021330T3 (pt)
EA (1) EA019386B1 (pt)
EC (1) ECSP088854A (pt)
ES (1) ES2350959T3 (pt)
HK (1) HK1131971A1 (pt)
HR (1) HRP20100700T1 (pt)
IL (1) IL194916A (pt)
JO (1) JO3602B1 (pt)
MX (1) MX2008014108A (pt)
MY (1) MY154595A (pt)
NI (1) NI200800290A (pt)
NO (1) NO341965B1 (pt)
NZ (1) NZ572251A (pt)
PE (1) PE20080065A1 (pt)
PL (1) PL2021330T3 (pt)
PT (1) PT2021330E (pt)
RS (1) RS51473B (pt)
SI (1) SI2021330T1 (pt)
TW (1) TWI419882B (pt)
UA (1) UA94749C2 (pt)
UY (1) UY30322A1 (pt)
WO (1) WO2007130780A2 (pt)
ZA (1) ZA200810234B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101503286B1 (ko) * 2006-12-15 2015-03-17 얀센 파마슈티카 엔.브이. 벤즈이미다졸 ｔｒｐｖ1 저해제
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
CL2008003749A1 (es) * 2007-12-17 2010-01-15 Janssen Pharmaceutica Nv Compuestos derivados de imidazol, oxazol, y tiazol pirimidina, moduladores de trpv1, proceso de preparacion, composicion farmaceutica y su uso en el tratamiento de enfermedades, trastornos o condicion de dolor, prurito, artritis, tos, asma, trastorno del oido interno y enfermedad inflamatoria intestinal, entre otras.
WO2009079000A1 (en) * 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolopyrimidine modulators of trpv1
KR101252334B1 (ko) * 2008-04-18 2013-04-08 주식회사 대웅제약 신규 벤조옥사진 벤즈이미다졸 유도체, 이를 포함하는 약학 조성물 및 이의 용도
US8232409B2 (en) 2008-10-15 2012-07-31 Janssen Pharmaceutica N.V. Heterocyclic benzimidazoles as TRPM8 modulators
US8217060B2 (en) * 2009-05-15 2012-07-10 Janssen Pharmaceutica, Nv Benzimidazole derivatives useful as TRP M8 receptor modulators
US8323805B2 (en) * 2009-06-04 2012-12-04 Nitto Denko Corporation Emissive aryl-heteroaryl acetylenes
CN102002010A (zh) * 2009-08-31 2011-04-06 住友化学株式会社 双噁唑啉基烷烃化合物的精制方法
DK2709619T3 (en) 2011-05-16 2018-01-15 Cellceutix Corp RELATIONSHIPS FOR USING THE TREATMENT OF MUCOSITIS
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
EP2970269B1 (en) 2013-03-14 2017-04-19 Novartis AG 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
EA201690152A1 (ru) * 2013-07-11 2016-05-31 Бристол-Майерс Сквибб Компани Ингибиторы ido
EP3089963A1 (en) 2013-10-30 2016-11-09 Novartis AG 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
WO2017043342A1 (ja) * 2015-09-08 2017-03-16 住友化学株式会社 トリアゾール化合物の製造方法
JP7041141B2 (ja) * 2016-11-01 2022-03-23 メルク・シャープ・アンド・ドーム・コーポレーション 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤
ES2949366T3 (es) * 2018-05-03 2023-09-28 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivados de bencimidazol como moduladores del receptor huérfano gamma relacionado con retinoides (rory) y usos farmacéuticos de los mismos
CN108997398B (zh) * 2018-07-23 2020-12-15 被忽略疾病药物研发组织 一种3,3-二甲基苯并[c][1,2]氧杂戊硼烷-1(3h)-醇的制备方法
TW202118751A (zh) * 2019-10-31 2021-05-16 大陸商江蘇恒瑞醫藥股份有限公司 RORγ調節劑的酸加成鹽
CN112745268B (zh) * 2019-10-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并咪唑衍生物的晶型及制备方法
US11771694B2 (en) 2020-06-05 2023-10-03 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US6299796B1 (en) 1997-12-18 2001-10-09 Fuji Photo Film Co., Ltd. Styryl compound, method for the preparation thereof and electroluminescent element employing the same
US6748803B1 (en) * 2000-02-22 2004-06-15 Simmonds Precison Products, Inc. Liquid measurement system and shared interface apparatus for use therein
JP2006505570A (ja) * 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
TW200418806A (en) * 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
EP1660491B1 (en) * 2003-07-28 2008-08-06 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
KR20060115396A (ko) * 2003-10-28 2006-11-08 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서 유용한 벤즈이미다졸
WO2006058338A2 (en) * 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
KR20090024789A (ko) * 2006-07-04 2009-03-09 얀센 파마슈티카 엔.브이. 치환 복소환기를 갖는 벤즈이미다졸 카나비노이드 작용제
KR101503286B1 (ko) * 2006-12-15 2015-03-17 얀센 파마슈티카 엔.브이. 벤즈이미다졸 ｔｒｐｖ1 저해제

Also Published As

Publication number Publication date
EP2021330A2 (en) 2009-02-11
CA2651128A1 (en) 2007-11-15
EP2021330B1 (en) 2010-09-22
DE602007009378D1 (de) 2010-11-04
JP2009535414A (ja) 2009-10-01
IL194916A0 (en) 2009-08-03
PT2021330E (pt) 2010-12-03
AR060840A1 (es) 2008-07-16
JP5302884B2 (ja) 2013-10-02
AU2007248341B2 (en) 2011-12-08
US20110190344A1 (en) 2011-08-04
US20110190364A1 (en) 2011-08-04
KR20090008428A (ko) 2009-01-21
CA2651128C (en) 2014-09-02
TW200808738A (en) 2008-02-16
UA94749C2 (en) 2011-06-10
RS51473B (en) 2011-04-30
ES2350959T3 (es) 2011-01-28
PE20080065A1 (es) 2008-02-25
AU2007248341A1 (en) 2007-11-15
ZA200810234B (en) 2010-02-24
CR10479A (es) 2009-03-31
US20070259936A1 (en) 2007-11-08
PL2021330T3 (pl) 2011-03-31
DK2021330T3 (da) 2010-12-06
UY30322A1 (es) 2007-08-31
NI200800290A (es) 2012-01-30
JO3602B1 (ar) 2020-07-05
CY1111269T1 (el) 2015-08-05
TWI419882B (zh) 2013-12-21
EA200870497A1 (ru) 2009-06-30
BRPI0709803B1 (pt) 2019-12-10
HK1131971A1 (en) 2010-02-12
EA019386B1 (ru) 2014-03-31
BRPI0709803A2 (pt) 2011-07-26
NO341965B1 (no) 2018-03-05
ATE482201T1 (de) 2010-10-15
WO2007130780A3 (en) 2008-02-14
MX2008014108A (es) 2008-11-14
CO6160329A2 (es) 2010-05-20
NZ572251A (en) 2010-08-27
AU2007248341C1 (en) 2013-01-17
WO2007130780A2 (en) 2007-11-15
US7951829B2 (en) 2011-05-31
SI2021330T1 (sl) 2011-01-31
CN101511797A (zh) 2009-08-19
MY154595A (en) 2015-06-30
ECSP088854A (es) 2008-11-27
NO20085031L (no) 2009-01-06
HRP20100700T1 (hr) 2011-02-28
IL194916A (en) 2013-01-31
KR101434883B1 (ko) 2014-08-27
CN101511797B (zh) 2013-01-02

Similar Documents

Publication Publication Date Title
BRPI0709803B8 (pt) compostos moduladores de benzimidazol de vr1, sais, processo de preparação do mesmo, seu uso e composição farmacêutica que os compreende
BRPI0916735B8 (pt) compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
ECSP066856A (es) Compuestos novedosos como moduladores del receptor opioide
BR112014010576B8 (pt) compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos
UY30610A1 (es) Moduladores de mglur5
CR11857A (es) Compuestos pirazolicos 436
CR10778A (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiaxol-5-ona, procedimientos para su preparacion y su uso como agentes farmaceuticos
BR112013016595A2 (pt) inibidores de neprilisina
BRPI0918750B8 (pt) derivado de 2-carboxamida cicloamino ureia, seu uso e sua composição farmacêutica
SV2009003346A (es) Compuestos triciclicos, composiciones y procedimientos.
EA201170772A1 (ru) Органические соединения
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
NO20083553L (no) Indolsulfonamidmodulatorer av progrestonreseptorer
ECSP066536A (es) Derivados de acidos fenoxiaceticos utiles como agonistas dobles dereceptor activado por proliferador de peroxisoma
ECSP088884A (es) Compuestos heterociclicos fusionados y su uso como moduladores de mglur5
BRPI0913291A2 (pt) composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
EA200901389A1 (ru) Производные фталазина и изохинолина с модулирующим действием на s1p рецепторы
BR112013008211A8 (pt) Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende
UY31981A (es) Oxazolopirimidinas como agonistas del receptor edg-1
BRPI0718436B8 (pt) compostos antagonistas do receptor b1 da bradicinina derivados de fenilsulfamoilbenzamida, processo para preparar os mesmos, uso dos mesmos e composição farmacêutica
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
CR11584A (es) Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/04/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF